Phytoecdysone and / or 20-hydroxyecdysone derivatives in combination with an active ingredient for restoring SMN expression for use in the treatment of spinal muscular atrophy - Patent Application 20100233331

Combining semi-synthetic phytoecdysone derivatives with SMN protein-enhancing agents provides a synergistic treatment for SMA, improving functional outcomes and survival beyond current therapies.

JP2024542447APending Publication Date: 2024-11-15BIOPHYTIS +3
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024528525
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-10
Filing Date
2022-11-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current treatments for spinal muscular atrophy (SMA) face limitations such as invasive administration methods, incomplete symptom coverage, and potential side effects, despite increasing SMN protein expression, which do not fully address the disease's progression and patient quality of life.

Method used

Combining semi-synthetic derivatives of phytoecdysone and/or 20-hydroxyecdysone with active ingredients that enhance SMN protein production, such as gene therapy or antisense oligonucleotides, to achieve a synergistic effect in treating SMA.

Benefits of technology

The combination therapy significantly improves motor and functional performance, survival, and body weight in SMA animals by enhancing SMN protein production, offering a complementary approach to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542447000007
    Figure 2024542447000007
  • Figure 2024542447000008
    Figure 2024542447000008
  • Figure 2024542447000009
    Figure 2024542447000009
Patent Text Reader

Abstract

The present invention relates to at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone, and at least one active ingredient capable of increasing the production of functional SMN protein, for use in combination therapy in treating spinal muscular atrophy in a mammal.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of semi-synthetic derivatives of phytoecdysone and / or 20-hydroxyecdysone in combination with an active ingredient aimed at restoring the expression of the survival of motor neurons (SMN) protein, for the treatment of spinal muscular atrophy. [Background technology]

[0002] Neuromuscular diseases are characterized by altered function of the motor unit, which consists of motor neurons, neuromuscular junctions, and skeletal muscles. Regardless of the origin of the disease, whether neurological, such as spinal muscular atrophy and amyotrophic lateral sclerosis, or muscular, they all alter the motor function of the patient and, if vital muscles are affected, can lead to disability and even premature death.

[0003] Among these neuromuscular diseases, two specifically affect motor neurons: childhood spinal muscular atrophy (or SMA), which manifests in childhood, and amyotrophic lateral sclerosis (or ALS), which manifests in adulthood. Although these two neurodegenerative diseases have different causes and clinical symptoms, they share a common cause: progressive muscle denervation, which leads to muscle atrophy (Al-Chalabi and Hardiman, 2013; Crawford and Pardo, 1996).

[0004] Spinal muscular atrophy is the most common genetic cause of infant death, with a prevalence of 1 / 6,000 to 1 / 10,000 births (Crawford and Pardo, 1996). There are three main types of disease, ranging from type 1, the most severe, to type 3, in which life expectancy can exceed 40 years, depending on the age at which symptoms appear and the progression of clinical impairment. In SMA patients, skeletal muscles are affected symmetrically due to atrophy of muscle fibers that are isolated or organized into fascicles. Nearly all SMA is proximal, which is said to affect primarily the muscles of the trunk and adjacent areas. Motor defects gradually spread, first affecting the muscles of the lower limbs and then the muscles of the upper limbs, especially the extensors. The gene responsible for SMA was identified in 1995 on chromosome 5 and was named SMN, for "survival of motor neuron" (Lefebvre et al., 1995).

[0005] Despite the great clinical diversity, genetic analyses have demonstrated that all forms of SMA are caused by homozygous alterations in the SMN1 (survival of motor neurons) telomeric gene, which prevents the production of Smn protein and induces motor neuron degeneration, muscle atrophy, and weakness. In the human genome, an anticentromeric copy of this gene, the SMN2 gene, exists, which, although there are several copies of this gene (Lorson et al., 1998), can only partially compensate for the loss of function of the SMN1 gene. In fact, SMN2 has five nucleotides that differ from SMN1, one of which is in exon 7, which is prone to excision by splicing in 90% of the mRNAs produced by the SMN2 gene. This alternative splicing generates a truncated and unstable SMNΔ7 protein. Thus, only 10% of the proteins produced by the SMN2 gene are complete and functional (Lefebvre et al., 1997; Vitte et al., 2007). It has been demonstrated that there is an association between the copy number of the SMN2 gene, its expression level, and disease severity.

[0006] For SMN1-related proximal spinal muscular atrophy, several therapeutic strategies are in different stages of development: some of them aim to increase the amount of functional SMN protein by modifying the maturation of SMN2 messenger RNA and reintegrating the missing exon 7 (nusinersen, risdiplam, branapram) or by introducing the SMN1 gene by gene therapy (ZOLOGENSMA®).

[0007] Other strategies aim to slow the progression of the disease by protecting motor neurons or by improving the function of the neuromuscular junction (salbutamol, pyridostigmine) or muscle performance (SRK-015, physical training). Nevertheless, the majority of therapeutic approaches tested in SMA aim to increase the expression levels of the SMN protein, locally in the central nervous system and / or more commonly peripherally in other organs.

[0008] Gene therapy using adeno-associated virus (AAV) vectors to deliver the SMN1 gene has shown significant beneficial effects in preclinical studies in mice and in human clinical trials (Mendell et al., 2017; Passini et al., 2010; Lowes et al., 2018). Other approaches focused on modulating SMN2 splicing have also proven their efficacy (Naryshkin et al., 2014; Palacino et al., 2015; Finkel et al., 2016; Finkel et al., 2017). These highly positive results have enabled regulatory approval for certain molecules.

[0009] Currently, there are three treatments available for SMA: - The first approved treatment for SMA is SPINRAZA® (nusinersen). This treatment received marketing authorization (MA) in the United States in December 2016 and in Europe in June 2017. It is an antisense oligonucleotide (ASO) developed to increase the production of functional SMN protein by affecting the maturation (splicing) of the SMN2 gene. As antisense oligonucleotides do not cross the blood-brain barrier, nusinersen must be administered intrathecally on a regular basis. This allows re-expression of the SMN protein in motor neurons, which provides real clinical benefit, but the re-expression is of varying importance depending on the type of SMA and the age at which treatment is started. The sequences of antisense oligonucleotides capable of modifying the splicing of the SMN2 gene are shown in the applications WO 2007 / 002390 and WO 2018 / 014041. - Recently, ZOLGENSMA® (onasemnogene abeparvovec or AVXS-101), a gene therapy product aimed at delivering the SMN1 gene using a viral vector (AAV), was approved (MA in the US in May 2019 and conditional MA in Europe in May 2020). It is administered intravenously, making it easy to administer alone. - Finally, EVRYSDI® (risdiplam or RO7034067) was more recently approved (US in August 2020 and MA in March 2021 in Europe). EVRYSDI is a small molecule that acts on the maturation of the SMN2 gene and is administered daily orally or via feeding tube.

[0010] Although restoration of the SMN gene has resulted in unprecedented improvements in patients' functional assessments and motor function, individuals with SMA persist with significant deficits following treatment, even with early intervention ( Mercuri et al., 2018 ; Finkel et al., 2017 ; Baranello et al., 2018 ).

[0011] Preclinical studies have demonstrated these post-treatment defects in SMA mouse models, with treated animals exhibiting shorter life expectancy and reduced body weight, muscle mass, and function compared to healthy animals ( Passini et al., 2010 ; Hua et al., 2010 , 2011 ; Feng et al., 2016 ).

[0012] Other limitations and significant concerns regarding these treatments remain. For example, nusinersen must be administered several times a year via highly invasive intrathecal injections. This method of administration is very difficult and sometimes impossible for patients who have undergone surgery for scoliosis, so in these patients nusinersen is excluded as a treatment option. Intrathecal administration also results in specific distribution in the central nervous system, which means that not all symptoms can be fully covered. In this last respect, onasemnogene has the advantage that it is administered intravenously and allows systemic distribution. Nevertheless, the issue of bioavailability of the AAV9 serotype is still open, along with the fact that long-term transgene expression should be restricted to postmitotic cells such as neurons (Chaytow et al., 2021). Although onasemnogene is promoted as a therapy that requires only a single injection, it remains unclear whether the treatment will last for the patient's lifetime or whether booster shots will be required.

[0013] Risdiplam is a systemic therapy and is minimally invasive because it is administered orally daily. However, to the extent that risdiplam targets the splicing machinery, it may also affect other transcripts, causing unknown and uncontrollable non-targeted side effects. In fact, it has been reported that risdiplam appears to affect regulators of cell division at high concentrations, raising concerns about carcinogenic side effects (Ratni et al., 2018).

[0014] Phytoecdysones are an important family of polyhydroxylated sterols. These molecules are produced by many different species of plants (ferns, gymnosperms, and angiosperms) and are involved in defense against pests. The majority of phytoecdysones in the plant kingdom are 20-hydroxyecdysones.

[0015] French Patent Application 3021318 discloses that phytoecdysones, more specifically 20-hydroxyecdysone (20E), have been the subject of many pharmacological studies. These studies highlight the antidiabetic and anabolic properties of this molecule. A stimulatory effect on protein synthesis in muscle has been observed in vivo in rats (Syrov et al., 2000; Toth et al., 2008; Lawrence et al., 2012) and in vitro in C2C12 mouse myotubes (Gorelick-Feldman et al., 2008). Some of the effects mentioned above in animal models have been confirmed in clinical studies, which are still few in number. Thus, 20E promotes muscle mass gain in young athletes (Simakin et al., 1988).

[0016] Finally, French Patent Application Publication No. 1902726 further reports the use of phytoecdysone and its semi-synthetic derivatives for treating neuromuscular diseases, in particular childhood spinal muscular atrophy and amyotrophic lateral sclerosis (Latil et al., 2020).

[0017] The above factors indicate that although therapies that increase SMN protein expression may have a significant effect on disease progression and patient quality of life, it would still be useful to find complementary therapeutic approaches that reduce the dosage or frequency of administration of already approved therapeutic agents, or ultimately improve functional benefit to further reduce the burden of the disease. [Prior art documents] [Patent documents]

[0018] [Patent Document 1] International Publication No. 2007 / 002390

Patent Document 2

Patent Document 3

Non-Patent Document

[0019]

Non-Patent Document 1

Non-Patent Document 2

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

Outdoor Configuration6

Direct Environment 7

Outdoor Track 8

Outdoor Content11

Outdoor Tools 12

Outdoor Content13

Outdoor Tools 14

Outdoor Tools 15

Outdoor Content 16

Outdoor Track 17

Outdoor Tools 18

Outdoor Tools 19

Non-Patent Document 20

Non-Patent Document 21

Non-Patent Document 22

Non-Patent Document 23

[0020] The present invention aims to provide a therapeutic agent for spinal muscular atrophy which is improved compared to existing therapeutic agents.

[0021] The present inventors have unexpectedly discovered that phytoecdysone (particularly 20E and its semi-synthetic derivatives) exhibit beneficial and synergistic effects when used in combination therapy with an active ingredient capable of increasing the production of functional SMN protein in mammals afflicted with spinal muscular atrophy. Indeed, when at least one semi-synthetic derivative of phytoecdysone and / or 20-hydroxyecdysone is used in combination with a therapeutic agent using an active ingredient capable of increasing the production of functional SMN protein, the synergistic effects of these elements improve the motor and functional performance, as well as the survival rate and body weight of animals afflicted with spinal muscular atrophy (SMA).

[0022] To achieve this goal, the present invention is directed to at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone, and at least one active ingredient capable of increasing the production of functional SMN protein, for use in combination therapy in the treatment of spinal muscular atrophy.

[0023] In a particular embodiment of the invention, the invention relates to at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone and at least one active ingredient capable of increasing the production of functional SMN protein for use in combination therapy in the treatment of motor neuron diseases involving SMA.

[0024] In the context of this application, the term "combination therapy" refers to the simultaneous administration of at least two biologically active agents. In the present case, the first active agent is selected from phytoecdysone or a semi-synthetic derivative of 20-hydroxyecdysone or is a composition comprising at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone, and the second active agent is an active ingredient capable of increasing the production of functional SMN protein. The combination therapy may comprise a single formulation or several formulations. The simultaneous administration can be simultaneous or sequential. The simultaneous administration may be by the same or different routes of administration. As long as the effects of the two (or more) agents overlap in the subject, resulting in an additive, additive or synergistic clinical effect, the therapy is considered a combination therapy.

[0025] In particular embodiments, the present invention further comprises the following features, which may be implemented separately or in any technically operable combination with each other:

[0026] In a particular embodiment, the at least one phytoecdysone and / or the at least one semi-synthetic derivative of 20-hydroxyecdysone and the at least one active ingredient capable of increasing the production of functional SMN protein are co-administered.

[0027] In certain embodiments, the at least one phytoecdysone and / or the at least one semi-synthetic derivative of 20-hydroxyecdysone and the at least one active ingredient capable of increasing the production of functional SMN protein are co-administered in the same composition.

[0028] In certain embodiments, the at least one phytoecdysone and / or the at least one semi-synthetic derivative of 20-hydroxyecdysone is orally or systemically administered to a mammal, and the at least one active ingredient capable of increasing the production of functional SMN protein is orally and / or intrathecally and / or intravenously administered to a mammal.

[0029] For oral administration, the at least one phytoecdysone and / or the at least one semi-synthetic derivative of 20-hydroxyecdysone and / or the active ingredient capable of increasing the production of functional SMN protein is preferably incorporated into an orally administrable pharma- ceutically acceptable formulation.

[0030] Gene therapy or gene therapy can increase the production of SMN protein. In one embodiment of gene therapy, the active ingredient capable of increasing the production of SMN protein aims to provide the SMN1 gene. In one embodiment of gene therapy, the active ingredient capable of increasing the production of SMN protein is either a small molecule acting on the maturation of the SMN2 gene, or an antisense oligonucleotide (ASO) developed to increase the production of functional SMN protein by acting on the splicing (maturation) of the SMN2 gene. In the latter case, the ASO regulates the splicing of SMN2. This increases the incorporation of exon 7 into the SMN2 mRNA, thus increasing the production of SMN protein with the amino acids corresponding to exon 7 and thus to the functional SMN protein.

[0031] Thus, in certain embodiments of the invention, the active ingredient has the ability to increase the production of functional SMN protein by gene therapy or gene treatment.

[0032] In certain embodiments of the invention, the active ingredient has the ability to increase the production of functional SMN protein by providing the SMN1 gene.

[0033] In certain embodiments of the invention, the active ingredient has the ability to increase the production of functional SMN protein by affecting the maturation of the SMN2 gene.

[0034] In a particular embodiment, the active ingredient capable of increasing the production of functional SMN protein is an antisense oligonucleotide (ASO). The ASO preferably has a sequence of 10-30 nucleotides, more preferably 12-30 nucleotides, more preferably 12-25 nucleotides, even more preferably 15-20 nucleotides. According to a preferred embodiment of the invention, the ASO has a sequence of 18 nucleotides.

[0035] In a specific embodiment of the invention, the ASO is capable of inducing exon 7 into the sequence of the SMN2 gene.

[0036] In certain embodiments of the invention, the ASO is at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90%, preferably at least 95%, most preferably 98%, preferably 100% complementary to the nucleic acid sequence encoding the pre-mRNA of the human SMN2 gene.

[0037] In a particular embodiment of the invention, the ASO is at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90%, preferably at least 95%, most preferably 98%, preferably 100% complementary to a sequence belonging to intron 6, intron 7, or part of exon 7 and part of the intron adjacent to exon 7 of a nucleic acid encoding the pre-mRNA of the human SMN2 gene. Thus, exon 7 is included in the mRNA of SMN2, making it possible to obtain a functional SMN protein.

[0038] The sequence of the nucleic acid encoding the pre-mRNA of the human SMN2 gene is available from Genbank under the reference number NG_008728, version NG_008728.1.

[0039] In a particular embodiment, the ASO is at least 50% identical or similar to SEQ ID NO:1 (5'-TCACTTTCATAATGCTGG-3') in the sequence listing attached to this application, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90% identical or similar, and preferably 100% identical or similar. SEQ ID NO:1 is complementary to 18 bases (bases 10 to 27) of intron 7 of the SMN2 gene.

[0040] In certain embodiments, the ASO has a sequence selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29. These sequences target the ASO to intron 7 of the SMN2 gene.

[0041] If the percentage of identity or similarity between the ASO sequence and one of the sequences listed above is less than 100%, the ASO sequence can be said to be a sequence in which this reference sequence has insertions, deletions, and / or substitutions.

[0042] The percent identity between two ASO sequences is determined by comparing the two optimally aligned sequences over a comparison window, such that the portion of the ASO sequence within the comparison window contains additions or deletions of the reference sequence that allow for optimal alignment between the two sequences.

[0043] The percentage of matches is calculated by determining the number of positions in the two compared sequences where the nucleobases are identical, then dividing this number of positions by the total number of positions in the comparison window, and multiplying the resulting number by 100.

[0044] ASOs preferably consist of a phosphodiester backbone, and may be variously modified in their backbone and / or their chemical structure to increase their stability and / or affinity for RNA and / or to confer significant pharmacokinetic advantages.

[0045] In certain embodiments, the ASO comprises at least one modification selected from the following: - modifications at the phosphate group, such as phosphorothioates, methylphosphanates or phosphoramidates; - chemical modifications at the 2' position of the ribose, such as 2'O-methyl (2'OMe), 2'O-methoxyethyl (2'MOE) or 2'fluoro (2'F); - at least one modification of the nucleobase, such as methylation of 5' methylcytosine, 5-methyluridine / ribothymidine or "G-clamp" type pyrimidine, - at least one substantial change in the sugar structure to generate various molecules such as morpholinos ("phosphoramidate morpholino oligomers" (PMO)), peptide nucleic acids (PNAs), or constrained oligonucleotides ("locked nucleic acids" (LNA), "2'-4'-constrained ethyl" (cEt), or tricyclo-DNA (tc-DNA)).

[0046] In certain embodiments, the ASO is a sequence that is at least 50% identical or similar, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90% identical or similar, and preferably 100% identical or similar to SEQ ID NO: 23. SEQ ID NO: 23 corresponds to SEQ ID NO: 1, which has 2'-O-methoxyethyl on the 2' carbon atom of deoxyribose at each base, further having a phosphorothioate backbone and 5-methylcytosine instead of cytosine. The phosphorothioate backbone advantageously improves the stability of the ASO, the 5-methylcytosine advantageously reduces the susceptibility of the ASO to nucleases, and the 2'-O-methoxyethyl on the 2' carbon atom of deoxyribose advantageously reduces the immune response induced by administration of the ASO.

[0047] In a specific embodiment of the invention, the ASO is administered at a dose of 0.01-10 mg / kg human, preferably once a day or once a week.

[0048] The semi-synthetic derivatives of phytoecdysone and 20-hydroxyecdysone are advantageously purified to pharmaceutical grade for use in the present invention.

[0049] A phytoecdysone which can be used according to the invention is, for example, 20-hydroxyecdysone.

[0050] To this end, according to a particular embodiment of the invention, said at least one phytoecdysone is 20-hydroxyecdysone.

[0051] 20-hydroxyecdysone and its semi-synthetic derivatives are advantageously purified to pharmaceutical grade.

[0052] The 20-hydroxyecdysone used is preferably in the form of a plant extract rich in 20-hydroxyecdysone or a composition containing 20-hydroxyecdysone as active agent, such as the extracts of Stemmacantha carthamoides (also known as Leuzea carthamoides), Cyanotis arachnoidea and Cyanotis vaga.

[0053] The resulting extract is preferably purified to pharmaceutical grade.

[0054] In one embodiment, the 20-hydroxyecdysone is in the form of a plant extract or plant part, said extract comprising at least 95%, preferably at least 97%, of 20-hydroxyecdysone. Preferably, said plant is selected from plants containing at least 0.5% 20-hydroxyecdysone by dry weight of said plant. Preferably, said extract is purified to pharmaceutical grade.

[0055] The extract is then referred to as BIO101. BIO101 is notable for containing 0-0.5% impurities by dry weight in the extract, e.g., trace compounds that may affect the safety, availability, or efficacy of the extract for medicinal use.

[0056] Preferably, the plant from which BIO101 is produced is selected from Stemacantha carthamoides, Cyanotis arachnoidea, and Cyanotis vaga.

[0057] Semisynthetic derivatives of 20-hydroxyecdysone can be obtained by semisynthesis, in particular by the method described in EP-A-15732785.9.

[0058] In a particular embodiment, phytoecdysone is administered at a dosage of 3 to 15 milligrams per kilogram human per day. As used herein, the term "phytoecdysone" refers generally to both phytoecdysone, 20-hydroxyecdysone (particularly in the form of extracts) and semi-synthetic derivatives thereof.

[0059] Preferably, phytoecdysone is administered to a human adult in a dose of 200-1000 mg / day in single or divided doses, and to a human child or infant in a dose of 5-350 mg / day in single or divided doses.As used herein, the term "phytoecdysone" refers generally to both phytoecdysone, 20-hydroxyecdysone (especially in the form of extracts) and semi-synthetic derivatives thereof.

[0060] In a particular embodiment of the invention, said at least one semi-synthetic derivative of 20-hydroxyecdysone is selected from: - a compound of general formula (I):

[0061] [ka]

[0062] During the ceremony: R 1 is selected from: the (C-C)W(C-C) group; the (C-C)W(C-C)W(C-C) group; the (C-C)W(C-C)CO2(C-C6) group; the (C-C)A group, where A represents a heterocycle optionally substituted with groups of the type OH, OMe, (C-C), N(C-C), CO2(C-C6); and the CH2Br group; W is a heteroatom selected from N, O, and S, preferably O, more preferably S°; and - a compound having the formula (II)

[0063] [ka]

[0064] Within the scope of the present invention, the term "(C1-C6)" denotes any alkyl radical of 1 to 6 straight or branched carbon atoms, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl. Advantageously, it is a methyl, ethyl, iso-propyl or t-butyl radical, in particular a methyl or ethyl radical, more particularly a methyl radical.

[0065] Within the scope of the present invention, the term "heterocycle" preferably denotes a ring of 5 or 6 atoms including 1 or 2 heteroatoms (O, S or N), the remaining atoms being carbon atoms.

[0066] In a preferred embodiment of the present invention, in general formula (I): R 1is selected from: the (C1-C6)W(C1-C6) radical; the (C1-C6)W(C1-C6)W(C1-C6) radical; the (C1-C6)W(C1-C6)CO2(C1-C6) radical; and the (C1-C6)A radical, where A represents a heterocycle optionally substituted with radicals of the type OH, OMe, (C1-C6), N(C1-C6), CO2(C1-C6); W is a heteroatom selected from N, O, and S, preferably O, and more preferably S.

[0067] In a particular embodiment of the invention, said at least one semi-synthetic derivative of 20-hydroxyecdysone is a compound selected from the following compounds: No. 1: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-(2-morpholinoacetyl)-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 2: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(3-hydroxypyrrolidon-1-yl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 3: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(4-hydroxy-1-piperidyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 4: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-[4-(2-hydroxyethyl)-1-piperidyl]acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 5: (2S,3R,5R,10R,13R,14S,17S)-17-[2-(3-dimethylaminopropyl(methyl)amino)acetyl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 6: 2-[2-oxo-2-[(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-6-oxo-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]ethylsulfanyl acetate; No. 7: (2S,3R,5R,10R,13R,14S,17S)-17-(2-ethylsulfanylacetyl)-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 8: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(2-hydroxyethylsulfanyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one.

[0068] According to another aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone, - at least one active ingredient capable of increasing the production of functional SMN protein The present invention relates to a composition comprising:

[0069] Such use of the composition may meet one or more of the characteristics described above with reference to the use of the at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone and the at least one active ingredient capable of increasing the production of functional SMN protein in combination therapy.

[0070] In embodiments, the compositions are incorporated into a pharma- ceutically acceptable formulation that allows for oral, intrathecal, or systemic administration.

[0071] Within the scope of the present invention, the term "pharmaceutical acceptable" means useful for the preparation of pharmaceutical compositions, generally safe, non-toxic and acceptable for human medical use as well as veterinary use.

[0072] The invention will be better understood on reading the following description, which is explained by way of non-limiting example with reference to the figures which represent: For each figure, the results are shown as the mean ± SEM. * indicates p<0.05. ** indicates p<0.01. *** indicates p<0.001, **** indicates p<0.0001. Another explanation is that n corresponds to the sample size, p corresponds to the "p-value" used to quantify the statistical significance of a result, and p=ns indicates that the p-value is not significant. [Brief description of the drawings]

[0073] [Figure 1] 1 shows curves of body weight progression from mouse birth (P0) to death for SMA mice (SmnΔ7 / Δ7; huSMN2+ / -) treated with BIO101 alone or mismatched ASO or ASO10-27 alone or in combination with BIO101. As used herein and elsewhere, P corresponds to days after birth (postnatal). [Diagram 2]Kaplan-Meier representation of survival curves from birth (P0) of SMA mice (SmnΔ7 / Δ7; huSMN2+ / -) treated with BIO101 alone or mismatch ASO or ASO10-27 alone or ASO10-27 in combination with BIO101. [Diagram 3] The motor performance (locomotor ability) was assessed in the open field test from birth (P0) for SMA mice (SmnΔ7 / Δ7; huSMN2+ / -) treated with BIO101 alone or mismatch ASO or ASO10-27 alone or in combination with ASO10-27 and BIO101. [Figure 4] Motor performance (muscle fatigue) assessed by grip strength test from birth (P0) is shown for SMA mice (SmnΔ7 / Δ7; huSMN2+ / -) treated with BIO101 alone, mismatch ASO, ASO10-27 alone, or ASO10-27 in combination with BIO101. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0074] The present invention will now be described in the particular context of one preferred, non-limiting field of application thereof.

[0075] 1. Description and Injection of Antisense Oligonucleotides (ASOs) Also known as ISIS-SMNRx, and alternatively referred to as ASO10-27, it is complementary to 18 bases (bases 10 to 27) of intron 7 of the SMN2 gene, which has at each base a modified nucleotide 2'-O-methoxyethyl on the 2' carbon atom of the deoxyribose (targeting a site within intron 7, called ISS-N1, which inhibits the incorporation of exon 7 of the pre-messenger RNA (pre-mRNA) of the SMN2 gene) SEQ ID NO:2 of reference ISIS396443 Antisense oligonucleotides (ASOs) of sequence 3 (5'-TCACTTTCATAATGCTGG-3') with a phosphorothioate backbone and 5-methylcytosine and a control ASO (denoting a mismatch) of sequence ID No. 24 (5'-TTAGTTTAATCACGCTCG-3') were synthesized and purified as previously described (Singh et al., 2006; Williams et al., 2009) (Baker et al., 1997; Hua et al., 2008; Passini et al., 2011). Oligonucleotides were resuspended in 0.9% NaCl at a concentration of 8 μg / μL and stored at -20°C.

[0076] On the day of injection, ASO stock solution is diluted with 0.9% NaCl to a concentration of 2 μg / μL. 0.04% methylene blue is added to the solution as an injection control. Postnatal day 1 (P0) neonatal SMA mice receive a single unilateral intraventricular injection of 8 μg of ASO10-27 or ASO mismatch using a Hamilton syringe and a 32G needle. At P0, the injection site is located 1 mm from the sagittal suture between bregma and lambda. The needle is placed perpendicular to the injection site on the skin surface and penetrated to a depth of approximately 3 mm to reach the lateral ventricle.

[0077] 2. Coadministration of BIO101 The supplemental therapeutic agent BIO101 complexed with cyclodextrin is orally administered daily via pipette to mice starting from postnatal day 1 (P0) at a dose of 50 mg / kg.

[0078] 3. Biological activity of BIO101 in combination with ASO a. Analysis of the effects of the combined treatment ASO10-27 + BIO101 on body weight and survival rate We have used a mouse Smn gene that has been modified to nullify exon 7 and express the human SMN2 transgene (Smn Δ7 / Δ7 ;huSMN2 - / + We used a severe SMA mouse model on the Friend leukemia virus B / NOD Rag-2 Jak3-deficient (FVB / NRj) genetic background, which is characterized by the expression of two copies of the genotype “FVB / NRj-Smn Δ7 / Δ7 huSMN2 - / + Mice resulting from these crosses carrying "two copies of β-terminal β-terminal nucleotides" are described as "SMA" (Hsieh et al., 2000). SMA mice were treated with either BIO101 alone or mismatched ASO, or ASO10-27 alone or combined ASO10-27 and BIO101 treatment from P0. Mice were analyzed daily for survival (Figure 1) and body weight (Figure 2).

[0079] The median life span of pups treated with BIO101 alone (Figure 1) (11 days) is nearly identical to that of pups treated with mismatched ASO (13 days). As reported by Passini et al. in 2011, monotherapy with ASO10-27 at a dose of 8 μg significantly increased the median life span of SMA pups, with a median survival of 18 days (a 38% improvement in animal survival) compared to a median survival of 13 days for the mismatched ASO control group. When BIO101 treatment was administered in combination with ASO10-27, the median survival increased to 22.5 days, i.e., a 73% improvement in animal survival.

[0080] The body weights of pups treated with BIO101 alone (Figure 2) are similar to those of pups treated with the mismatch ASO throughout their lives.

[0081] Treatment with ASO10-27 alone did not increase the mean body weight of SMA mice compared to control treatment with mismatch ASO at P7, but significantly increased it by 9.9% at P8 and 13.9% at P9. The combination of ASO10-27 and BIO101 induced a synergistic effect on the body weight of SMA pups, significantly increasing it by 11.3% at P7, 16.5% at P8, and 24.9% at P9.

[0082] At P10, treatment with ASO10-27 alone significantly increased the mean body weight of SMA pups (+16%) compared to control treatment with mismatched ASO. In combination with ASO10-27, BIO101 induced a synergistic effect on the body weight of SMA pups, with body weight significantly increased by +30.9% at P10 (p<0.05), i.e., nearly twice as much as that observed with ASO10-27 alone.

[0083] The weight of pups treated with ASO10-27+BIO101 was greater than that of pups treated with ASO10-27 alone, continuing until death, with significant increases in weight of 33% (p<0.05) at P15, 49.4% (p<0.05) at P20, and 57.6% (p<0.01) at P25.

[0084] b. Analysis of the functional effects of ASO10-27+BIO101 combination treatment Mice with severe SMA type 2 treated with BIO101 alone or mismatched ASO, or ASO10-27 alone or ASO10-27 and BIO101 combination therapy were phenotyped at P0. The mice were monitored for motor ability in the horizontal direction. Meanwhile, motor ability was evaluated by the open field test (Figure 3) and muscle fatigue was evaluated by the grip test (Figure 4) as in previous papers (Biondi et al., 2008; Branchu et al., 2013; Chali et al., 2016).

[0085] The apparatus used for the open field test consisted of a plastic box of size 28 × 28 × 5 cm with a field grid divided into 16 tiles of 7 cm × 7 cm. Mice were tested individually and the evaluation apparatus was cleaned after each treatment. Initially, each mouse was placed in the center of the field and allowed to move freely for 5 min while receiving a tail pinch every 15 s. During this 5 min, the experimenter recorded behavioral measurements and recorded the total number of tiles visited.

[0086] Treatment with BIO101, either alone or in combination with ASO10-27, promoted locomotion, tending to increase mouse locomotion (110±18 or +58% for BIO101 alone and 100±19 or +44% for ASO10-27+BIO101) over pups treated with ASO10-27 alone (70±20) at P15.

[0087] From P23, the motor performance of pups treated with ASO10-27+BIO101 tended to be increased more than that of pups treated with ASO10-27 alone (+51.3%, p=ns), and was significantly increased at P25 (+38.4%, p<0.05) or even at P27 (+44.9%, p<0.01) (Figure 3).

[0088] To assess muscle fatigue, the grip strength of the mice's forelimbs was tested. The mice were hung by their forelimbs from a thin metal bar suspended horizontally in the air. The time spent hanging was recorded. Each mouse was tested five consecutive times, with a 1-minute rest between two tests. Only the best test result was retained for the assessment of muscle function.

[0089] At P7, the fatigue resistance of pups treated with ASO10-27 alone was not improved compared to that of pups treated with mismatch ASO. The fatigue resistance of mice treated with BIO101 alone improved by 19.3%. At P15, the fatigue resistance of both mice treated with ASO10-27 alone and BIO101 alone was higher (+7.7%) than that of pups treated with mismatch ASO. Surprisingly and advantageously, a synergistic effect between BIO101 and ASO10-27 was observed during combination treatment, increasing fatigue resistance of treated SMA animals by 26.3% at P7 and 21.2% at P15.

[0090] From P19, the fatigue resistance of pups treated with ASO10-27+BIO101 tends to increase compared to that of mice treated with ASO10-27 alone. This difference becomes evident from P21 (+54% in the group treated with the ASO10-27+BIO101 combination compared to ASO10-27 alone, p=ns), and then increases at P23 (+159.2%, p<0.05), P25 (+337.7%, p<0.05), or even P27 (+296.7%, p=0.07). These significant differences are maintained up to P35. From P39, these differences become less pronounced, but the group of mice treated with the ASO10-27+BIO101 combination still maintains a higher fatigue resistance than that observed in the group treated with ASO10-27 alone (Figure 4).

[0091] 4. Conclusion In particular, with the therapeutic approach using ASO having the effect of restoring SMN protein expression, these results demonstrate the importance of BIO101 therapeutics in combination with active ingredients aimed at restoring SMN protein expression.

[0092] Indeed, this combination therapy shows significant beneficial effects in a mouse model of SMA, in particular in terms of the body weight of the animals, and more notably in terms of the physical performance of these animals, either their exercise capacity or their fatigue resistance.

[0093] The combination of ASO10-27+BIO101 treatment undoubtedly has a synergistic effect beyond the improved performance provided by ASO10-27 treatment as monotherapy.

[0094] More generally, it should be noted that the implementations and embodiments of the invention discussed above are described by way of non-limiting examples, and thus other variations are possible.

[0095] In particular, the present invention has been described mainly by considering ASO10-27 of SEQ ID NO:23. However, in other types of embodiments, it is not excluded to consider other active ingredients capable of increasing the production of SMN protein, for example other ASOs capable of increasing the production of SMN protein. Such ASOs are, for example, ASOs of sequences selected from the following: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29.

[0096] These sequences are particularly shown in Table 1 below:

[0097] [Table 1] TIFF2024542447000004.tif62170

Claims

1. 2. The method of claim 1, further comprising administering to said mammalian subject at least one of said active ingredients a compound selected from the group consisting of at least one semi-synthetic derivative of at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone and at least one active ingredient capable of increasing the production of a functional survival of motor neuron (SMN) protein for use in the treatment of spinal muscular atrophy in a mammal.

2. 2. The method according to claim 1 for the treatment of a motor neuron disease leading to spinal muscular atrophy, comprising administering to said patient at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone as claimed in claim 1 and at least one active ingredient capable of increasing the production of functional SMN protein.

3. The motor neuron disease is a functional alteration of motor neurons or their degeneration, for use according to claim 2, comprising at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone as claimed in claim 2 and at least one active ingredient capable of increasing the production of functional SMN protein.

4. The active ingredient has the ability to increase the production of functional SMN protein by gene therapy or gene treatment, for use according to any one of claims 1 to 3, comprising at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone as claimed in any one of claims 1 to 3, and at least one active ingredient capable of increasing the production of functional SMN protein.

5. The active ingredient has the ability to increase the production of functional SMN protein by providing the SMN1 gene or by acting on the maturation of the SMN2 gene, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 1 to 3 for use according to any one of claims 1 to 3, and at least one active ingredient capable of increasing the production of functional SMN protein.

6. 4. At least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 1 to 3, wherein said active ingredient capable of increasing the production of a functional SMN protein is an antisense oligonucleotide, for use according to any one of claims 1 to 3, and at least one active ingredient capable of increasing the production of a functional SMN protein.

7. The antisense oligonucleotide comprises 10 to 30 nucleotides, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to claim 6 for use according to claim 6, and at least one active ingredient capable of increasing the production of a functional SMN protein.

8. The antisense oligonucleotide is at least 90%, preferably at least 95%, most preferably at least 98%, preferably 100% complementary to a nucleic acid sequence encoding the pre-mRNA of the human SMN2 gene, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to claim 6 or 7 for use according to claim 6 or 7, and at least one active ingredient capable of increasing the production of functional SMN protein.

9. The antisense oligonucleotide is at least 90%, preferably at least 95%, most preferably 98%, preferably 100% complementary to a sequence belonging to intron 6, intron 7 or exon 7 of a nucleic acid encoding the pre-mRNA of the human SMN2 gene, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 6 to 8 for use according to any one of claims 6 to 8, and at least one active ingredient capable of increasing the production of a functional SMN protein.

10. The antisense oligonucleotide has a sequence which is at least 50% identical or similar to SEQ ID NO:1, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90% identical or similar, preferably 100% identical or similar, and at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 6 to 9 for use according to any one of claims 6 to 9, and at least one active ingredient capable of increasing the production of functional SMN protein.

11. 10. The method of claim 1 further comprising administering to said subject the subject the ASO is a sequence selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 6 to 9 for use according to any one of claims 6 to 9 and at least one active ingredient capable of increasing the production of a functional SMN protein.

12. The ASO comprises at least one modification selected from the following: - modifications at the phosphate group such as phosphorothioates, methylphosphanates or phosphoramidates, - chemical modifications at the 2' position of the ribose, such as 2'O-methyl (2'OMe), 2'O-methoxyethyl (2'MOE) or 2'fluoro (2'F); - at least one modification of the nucleobase, such as methylation of 5' methylcytosine, 5-methyluridine / ribothymidine or "G-clamp" type pyrimidine, - at least one substantial change in the sugar structure to generate various molecules such as morpholinos, peptide nucleic acids, or constrained oligonucleotides.

12. The method of claim 11, comprising administering to said patient at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone as claimed in claim 6, and at least one active ingredient capable of increasing the production of a functional SMN protein, for use according to claim 6.

13. The antisense oligonucleotide has a sequence which is at least 50% identical or similar, preferably at least 60%, preferably at least 70%, more preferably at least 80%, most preferably at least 90% identical or similar, in particular 100% identical or similar to SEQ ID NO:23, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 6 to 9 for use according to any one of claims 6 to 9, and at least one active ingredient capable of increasing the production of functional SMN protein.

14. The at least one phytoecdysone is 20-hydroxyecdysone, and at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 1 to 13 for use according to any one of claims 1 to 13, and at least one active ingredient capable of increasing the production of functional SMN protein.

15. The 20-hydroxyecdysone is in the form of a plant extract or plant part, the extract comprising at least 95%, preferably at least 97%, of 20-hydroxyecdysone, and at least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone according to claim 14 for use according to claim 14, and at least one active ingredient capable of increasing the production of functional SMN protein.

16. The at least one semi-synthetic derivative of 20-hydroxyecdysone is: a compound of general formula (I): [Formula 1] During the ceremony: R 1 : (C 1 -C 6 ) W (C 1 -C 6 ) group; (C 1 -C 6 ) W (C 1 -C 6 ) W (C 1 -C 6 ) group; (C 1 -C 6 ) W (C 1 -C 6 ) CO 2 (C 1 -C 6 ) group; (C 1 -C 6 ) A group (A is OH, OMe, (C 1 -C 6 ), N(C 1 -C 6 ), CO 2 (C 1 -C 6 ) type heterocycles optionally substituted with groups of the formula CH 2 Br groups; W is a heteroatom selected from N, O, and S, preferably O, more preferably S; and - a compound having the formula (II) [Case 2] and at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone according to any one of claims 1 to 15 for use according to any one of claims 1 to 15 selected from the group consisting of at least one active ingredient capable of increasing the production of a functional SMN protein.

17. In general formula (I): R 1 : (C 1 -C 6 ) W (C 1 -C 6 ) group; (C 1 -C 6 ) W (C 1 -C 6 ) W (C 1 -C 6 ) group; (C 1 -C 6 ) W (C 1 -C 6 ) CO 2 (C 1 -C 6 ) group; (C 1 -C 6 ) A group (A is OH, OMe, (C 1 -C 6 ), N(C 1 -C 6 ), CO 2 (C 1 -C 6 )-type groups; W is a heteroatom selected from N, O and S, preferably O, more preferably S; at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone as described in claim 16 for use according to claim 16, and at least one active ingredient capable of increasing the production of functional SMN protein.

18. At least one compound of general formula (I) is No. 1: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-(2-morpholinoacetyl)-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 2: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(3-hydroxypyrrolidin-1-yl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 3: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(4-hydroxy-1-piperidyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 4: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-[4-(2-hydroxyethyl)-1-piperidyl]acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 5: (2S,3R,5R,10R,13R,14S,17S)-17-[2-(3-dimethylaminopropyl(methyl)amino)acetyl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 6: 2-[2-oxo-2-[(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-6-oxo-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]ethylsulfanyl acetate; No. 7: (2S,3R,5R,10R,13R,14S,17S)-17-(2-ethylsulfanylacetyl)-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; No. 8: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(2-hydroxyethylsulfanyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one 18. At least one phytoecdysone and / or at least one semi-synthetic derivative of 20-hydroxyecdysone according to claim 16 or 17, for use according to claim 16 or 17, selected from the group consisting of at least one active ingredient capable of increasing the production of functional SMN protein.

19. For use in treating spinal muscular atrophy in a mammal, at least one semi-synthetic derivative of at least one phytoecdysone and / or 20-hydroxyecdysone; - at least one active ingredient capable of increasing the production of a functional SMN protein; A composition comprising:

Citation Information

Patent Citations

  • Compositions and methods for modulation of SMN2 splicing in test subjects

    JP2012530715A

  • Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases

    WO2020187678A1

  • Chemical compounds and use thereof for improving muscular quality

    FR3021318A1

  • Compositions and methods for modulation of SMN2 splicing

    WO2007002390A2

  • Compounds and methods for modulation of SMN2

    WO2018014041A2